Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Glucose Tolerance
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in Body Composition
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in Resting Metabolic Rate
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in Brown Adipose Tissue Activity
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in Peripheral Insulin Sensitivity
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in Insulin Secretion
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in glycohemoglobin
Timeframe: 16 weeks (at baseline and at 16 weeks)
Change in Matsuda Index for Dosing Sub Study
Timeframe: Baseline, week 6, week 12, week 18
Change in bile acids/blood proteins
Timeframe: Baseline, week 1, week 2